AIM ImmunoTech, Inc. (AIM) - Final Profit

AIM ImmunoTech revenues are based on the commercialization of Ampligen for the treatment of oncology and rare pathologies. The company's total net income on this chart visualizes the financial return, where the current status equals -0.01. The business focuses on the immunological market and providing assistance to post-viral patients. Currently, the Ampligen platform has reached maturity, enabling the expansion of the clinical base for new regulatory approvals.

To identify fundamental leaders, the analyst evaluates net income as the final financial result after all expenses, where regular drawdowns signal hidden operational risks. In the case of AIM ImmunoTech (AIM), this metric reflects the monetization efficiency of patent monopolies on immunomodulators, allowing for an assessment of the transition from fixed R&D costs to ultra-high-margin sales via the company's profit chart.